Raising Awareness for Pancreatic Cancer "For my Brother Bones"
Back in July 2014 my brother Tony (Bones) Brennan was diagnosed with Stage 4 Pancreatic cancer.
His fight was quick and within one month of being diagnosed Bones was taken bye this devastating form of cancer. There were warning signs for my brother. Approx. 6-10 months prior to being diagnosed with pancreatic cancer Bones was having pains in his legs when playing football (soccer). He went to the doctors several times and was told that he had varicose veins and was advised to exercise. In reality although at the time we did not know he had blood clots in his legs. Eventually in June / July of 2014 it was only when Bones was having difficulty breathing that it was determined that he had bolod clots on his lungs due to the cancer spreading.
Upon finding out this over the next couple of weeks the doctors did some more tests a CT Scan and Biopsy to determine that the cancer had spread to his liver and it was at stage 4 cancer. Prior to recieving the actual biopsy results Bones suddenly passed away due to the cancer. It was devastating and surreal. It is now I find myself wanting to help grow awareness for pancfreatic cancer in support of not only my brother but for any and all that may or have been affected bye pancreatic cancer.
There needs to be more funding raised in which to support the research and development of new drugs and understanding of how to diagnose pancreatic cancer patients earlier.
Please support me in my quest to raise money for this well worth cause!!
SOME INFORMATION ABOUT PANCREATIC CANCER AND SURVIVAL RATES (www.pancreaticcancercanada.ca)
It has the highest mortality rate of all the major cancers – 92% of patients die within 5 years of their diagnosis and 75% of patients die within the first year.
It is the only leading cancer killer with a 5 year survival rate still in the single digits at 8% and the survival rate has not improved in the last 40 years.
It is referred to as a silent killer – it’s difficult to detect and spreads so quickly. Vague symptoms including back/abdominal pain, jaundice and nausea usually appear after the cancer is at an advanced stage making it difficult to treat.
More than 95% of pancreatic cancers are classified as exocrine tumors. These tumors start in the exocrine cells that make pancreatic enzymes that help in digestion. Within this category, the vast majority of tumors(90%) are adenocarcinomas where the cancer begins in cells lining the pancreatic duct.
Few patients diagnosed with pancreatic cancer have identifiable risk factors.
Pancreatic cancer is difficult to diagnose, and the diagnosis is often made late in the disease course. Symptoms include weight loss, back pain and jaundice.
Patients diagnosed with pancreatic cancer are encouraged to seek out clinical trials to improve pancreatic cancer treatment.
There are no detection tools to diagnose this disease in its early stages when surgical removal of the tumor is still possible. Surgery offers the best chance for long term survival. Only 15% of patients are diagnosed early enough to be eligible for surgery. The most common form of surgery for removal of a pancreatic tumor is the whipple procedure and may be followed with chemotherapy or a combination of chemotherapy/radiation.
For the patients who are not surgical candidates, chemotherapy or a combination of chemotherapy with radiation is typically offered. Chemotherapy after surgery can lower the chances of the cancer returning. Chemotherapy for metastatic pancreatic cancer can extend life and improve the quality of life for people with the disease.
Approximately 52% of all patients are diagnosed when the disease has spread to surrounding organs leaving little hope for survival (only 2% will survive five years).
Three drugs are currently being used to treat pancreatic cancer: gemcitabine (Gemzar®) and erlotinib (Tarceva). Folfirinox has been recently approved as a form of first-line treatment for metastatic pancreatic cancer in British Columbia and Ontario and case by case in selected provinces (Alberta, Manitoba and Quebec). in 2015, funding for Abraxane with Gemcitabine in all provinces was approved While these treatments can be beneficial in treating some patients, they are not considered curative.
If you think this page contains objectionable content, please inform the system administrator.